

THC Form 7

MONTHLY PROGRESS REPORT

May

Name of CSE Issuer **THC Biomed Intl Ltd.**
Trading Symbol: **THC**
Number of Outstanding Listed Securities **146,379,363 common shares and 43,236,193 reserved for Issuance**
Date: **June 7, 2019**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On May 9, the Issuer reported that it had entered into an agreement with the BC Liquor Distribution Branch ("BCLDB") to supply a number of its products exclusively to British Columbia. The agreement was entered into after the BCLDB met with the the Issuer's management and toured THC's flagship facility in Kelowna, B.C.

The BCLDB will provide purchase orders to the Issuer for the product quantities listed in the appendix to the agreement three months in advance of the available supply month.

The Issuer has committed to supplying all produced dried flower product intended for the non-medical market, exclusively to the BCLDB until December 2019, maintaining Wholesale Cost incl. Excise as listed in the appendix to the agreement until December 2019 and supplying the product as per the quantities and schedule listed in the appendix to the agreement.

The Issuer has agreed to exclusively supply the BCLDB with the following flower strains in 3.5-gram and 7-gram formats until December 2019; THC Sativa LANDRACE, THC Indica LANDRACE, THC Hybrid LANDRACE, THC CBD Indica LANDRACE, Atomical Haze, West Coast Dream, Original Cheese and Jacky White.

The Issuer will continue to supply all provinces with its best-selling pre-rolls as well as THC Kiss when the regulations permit. The Issuer also continues to work vigorously towards securing supply agreement with various provincial governments.

On May 22, the Issuer announced that they are engaging CFN Media to conduct a 6-month investor and market visibility program which began at the end of May, 2019. Compensation for the public markets program is USD \$10,000 per month.

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to educate high-quality investors on the Issuer's value proposition. CFN Media's program will measure investor engagement and identify interested investors via opt-in leads while elevating the Company's financial brand.

The Issuer also announced that John Miller, President, Chief Executive Officer and director of the Company plans on purchasing up to 500,000 additional common shares (the "Shares") in the Capital of the Company. The Issuer reported that the purchases will occur over a three week period ending on June 7, 2019. Mr. Miller is purchasing the Shares for investment purposes.

On May 29, the Issuer announced that it had entered into a line of credit with President, CEO and director John Miller for up to \$500,000 (the "Line of Credit"). Each separate draw down of funds from the Line of Credit ("Draw Down Amount") will not bear interest for the first three calendar months following its withdrawal, each Draw Down Amount becomes due and payable by the Issuer to Mr. Miller. In the event that a Draw Down Amount is not repaid on the business day following the last day of the third month following the withdrawal of that Draw Down Amount, then the Draw Down Amount will incur interest at a rate of the Prime Rate plus 1%. The interest will be calculated and payable monthly on the last business day of each month until the Line of Credit is repaid in full.

2. Provide a general overview and discussion of the activities of management.

See Item 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On May 9, the Issuer reported that it had entered into an agreement with the BC Liquor Distribution Branch ("BCLDB") to supply a number of its products

exclusively to British Columbia. The agreement was entered into after the BCLDB met with the THC's management and toured THC's flagship facility in Kelowna, B.C.

The BCLDB will provide purchase orders to the Issuer for the product quantities listed in the appendix to the agreement three months in advance of the available supply month.

The Issuer has committed to supplying all produced dried flower product intended for the non-medical market, exclusively to the BCLDB until December 2019, maintaining wholesale cost incl. excise as listed in the appendix to the agreement until December 2019 and supplying the product as per the quantities and schedule listed in the appendix to the agreement.

The Issuer has agreed to exclusively supply the BCLDB with the following flower strains in 3.5-gram and 7-gram formats until December 2019; THC Sativa LANDRACE, THC Indica LANDRACE, THC Hybrid LANDRACE, THC CBD Indica LANDRACE, Atomical Haze, West Coast Dream, Original Cheese and Jacky White.

The Issuer will continue to supply all provinces with its best-selling pre-rolls as well as THC Kiss when the regulations permit. The Issuer also continues to work vigorously towards securing supply agreement with various provincial governments.

The Issuer also announced that they are engaging CFN Media to conduct a 6-month investor and market visibility program which begun at the end of May, 2019. Compensation for the public markets program is USD \$10,000 per month.

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to educate high-quality investors on THC's value proposition. CFN Media's program will measure investor engagement and identify interested investors via opt-in leads while elevating the Company's financial brand.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

See Item 15.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

On May 29, the Issuer announced that it had entered into a line of credit with President, CEO and director John Miller for up to \$500,000 ("Line of Credit").

Each separate draw down of funds from the Line of Credit ("Draw Down Amount") will not bear interest for the first three calendar months following its withdrawal, each Draw Down Amount becomes due and payable by the Issuer to Mr. Miller. In the event that a Draw Down Amount is not repaid on the business day following the last day of the third month following the withdrawal of that Draw Down Amount, then the Draw Down Amount will incur interest at a rate of the Prime Rate plus 1%. The interest will be calculated and payable monthly on the last business day of each month until the Line of Credit is repaid in full.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Company's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Company's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at www.sedar.com.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **June 7, 2019**

John Miller

Name of Director or Senior Officer

"John Miller"

Signature

President and CEO

Official Capacity

Issuer Details		
Name of Issuer: THC Biomed Intl Ltd.	For Month End May	Date of Report: YYYYMMDD 2019/06/07
Issuer Address: P.O. Box 20033 Towne Centre		
City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. (250) 870-2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. (250) 870-2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	